News

Filter

Current filters:

GlaxoSmithKlineBenlysta

76 to 85 of 96305 results

Helsinn to present anamorelin Phase III data at European Society for Medical Oncology Congress

Helsinn to present anamorelin Phase III data at European Society for Medical Oncology Congress

25-09-2014

Family-run Swiss oncology specialist Helsinn is to present Phase III data on anamorelin at the 38th European…

anamorelinHelsinnOncologyPharmaceuticalResearchSwitzerland

GlaxoSmithKline confirms Sir Philip Hampton to be chairman

GlaxoSmithKline confirms Sir Philip Hampton to be chairman

25-09-2014

UK pharma giant GlaxoSmithKline this morning confirmed recent rumors, saying that Sir Philip Hampton…

BoardroomGlaxoSmithKlineManagementPharmaceuticalUKUnited Kingdom

Shire to pay $56.5 million in final agreement with US government

Shire to pay $56.5 million in final agreement with US government

25-09-2014

The US subsidiary of Ireland-headquartered Shire will pay $56.5 million to resolve civil allegations…

AbbVieAdderallFinancialLegalPharmaceuticalShireUSAVyvanse

Baxter and Merrimack enter exclusive licensing agreement for MM-398 compound outside the USA

Baxter and Merrimack enter exclusive licensing agreement for MM-398 compound outside the USA

24-09-2014

Baxter International and oncology specialist Merrimack have launched a collaboration to develop and commercialize…

Baxter InternationalBiotechnologyLicensingMerrimackMM-398OncologyUSA

Acorda Therapeutics to acquire Civitas for $525 million

24-09-2014

US biotech firm Acorda Therapeutics has entered into an agreement to acquire Civitas Therapeutics, a…

Acorda TherapeuticsBiotechnologyCivitas TherapeuticsCVT-301Mergers & AcquisitionsNeurological

Gilead files for Japanese approval of ledipasvir/sofosbuvir for hepatitis C

24-09-2014

Gilead Sciences has submitted a New Drug Application to Japan’s Pharmaceutical and Medical Devices…

Anti-viralsBiotechnologyGilead SciencesJapanledipasvirRegulationsofosbuvir

Inovio Pharma’s Ebola vaccine moving into Ph I with GeneOne Life Science

24-09-2014

US drug developer Inovio Pharmaceuticals has said it will advance its DNA vaccine for Ebola into a Phase…

GeneOne Life ScienceInovio PharmaceuticalsPharmaceuticalResearchTropical diseasesVaccines

Gilead's TAF-based HIV regimen meets 48-week primary objective

Gilead's TAF-based HIV regimen meets 48-week primary objective

24-09-2014

Gilead Sciences says that two Phase III clinical trials (Studies 104 and 111) evaluating an investigational…

Anti-viralsBiotechnologyGilead SciencesResearchtenofovir alafenamideUSA

76 to 85 of 96305 results

Back to top